Unknown

Dataset Information

0

Vitamin D supplementation in cutaneous malignant melanoma outcome (ViDMe): a randomized controlled trial.


ABSTRACT: Previous studies have investigated the protective effect of vitamin D serum levels, at diagnosis and during the follow-up period after treatment, on melanoma outcome. In the present study we assess whether vitamin D supplementation, in the follow-up period after diagnosis and surgical resection of the primary tumor, has a protective effect on relapse of cutaneous malignant melanoma and whether this protective effect correlates with vitamin D levels in serum and Vitamin D Receptor immunoreactivity in the primary tumor.This study is a multicenter randomized double blind placebo- controlled phase III trial. Patients between the age of 18 and 80 years diagnosed and treated surgically for a melanoma stage IB-III are eligible for randomization in a 1:1 ratio to active treatment or placebo. The study drug is taken each month and consists of either 100,000 International Unit cholecalciferol or arachidis oleum raffinatum used as a placebo. The primary endpoint is relapse free survival. The secondary endpoints are 25 hydroxyvitamin D3 serum levels at diagnosis and at 6 month intervals, melanoma subtype, melanoma site and stage of melanoma at diagnosis according to the 2009 American Joint Committee on Cancer melanoma staging and classification. At randomization a bloodsample is taken for DNA analysis. The study is approved by the local Ethics Committees.If we can confirm our hypothesis that vitamin D supplementation after removal of the tumor has a protective effect on relapse of cutaneous malignant melanoma we may reduce the burden of CMM at several levels. Patients, diagnosed with melanoma may have a better clinical outcome and improved quality of life. There will be a decrease in health care costs related to treatment of metastatic disease and there will be a decrease in loss of professional years, which will markedly reduce the economic burden of the disease.Clinical Trial.gov, NCT01748448 , 05/12/2012.

SUBMITTER: De Smedt J 

PROVIDER: S-EPMC5569491 | biostudies-literature | 2017 Aug

REPOSITORIES: biostudies-literature

altmetric image

Publications

Vitamin D supplementation in cutaneous malignant melanoma outcome (ViDMe): a randomized controlled trial.

De Smedt J J   Van Kelst S S   Boecxstaens V V   Stas M M   Bogaerts K K   Vanderschueren D D   Aura C C   Vandenberghe K K   Lambrechts D D   Wolter P P   Bechter O O   Nikkels A A   Strobbe T T   Emri G G   Marasigan V V   Garmyn M M  

BMC cancer 20170823 1


<h4>Background</h4>Previous studies have investigated the protective effect of vitamin D serum levels, at diagnosis and during the follow-up period after treatment, on melanoma outcome. In the present study we assess whether vitamin D supplementation, in the follow-up period after diagnosis and surgical resection of the primary tumor, has a protective effect on relapse of cutaneous malignant melanoma and whether this protective effect correlates with vitamin D levels in serum and Vitamin D Recep  ...[more]

Similar Datasets

| S-EPMC8226808 | biostudies-literature
| S-EPMC3866796 | biostudies-literature
| S-EPMC5627529 | biostudies-literature
| S-EPMC6437118 | biostudies-literature
| S-EPMC3808783 | biostudies-other
| S-EPMC4586731 | biostudies-literature
| S-EPMC3856388 | biostudies-literature
| S-EPMC3985208 | biostudies-literature
| S-EPMC2566998 | biostudies-literature
| S-EPMC5324802 | biostudies-literature